Header Information
-
Proposal Number:PPM 03-0311-190017
-
Program Cycle:PPM 03
-
Submitting Institution Name:Sidra Medicine
-
Project Status:Award Active
-
Start Date:
-
Lead Investigator:Dr. Ammira Al-Shabeeb Akil
-
Project Duration:3 Year(s)
-
End Date:
-
Submission Type:New
-
Proposal Title:The QGPRS Study: Qatar Genome Polygenic Risk Score, a precision Medicine Approach to Prevent Diabetic Complications in the affected Qatari Individuals
Project Summary
-
Proposal Description:
Nature of the proposed Research: A Precision Medicine Approach to Prevent Diabetic Complications in the Local Population of Qatar (the QGPRS Study). Context: Qatar is listed amongst the top 10 countries in the world with the highest prevalence (23%) of diabetes. Diabetes is the leading cause of cardiovascular and renal diseases that are both serious and costly. Improvement of the risk prediction is crucial to enable targeting individuals at high risk that could most benefit from an early prevention. However, this is most useful if prevention can be started early. Unfortunately, current clinical risk prediction algorithms are only applicable once clinical signs have been observed. Genetic information, with which one is born, offers a way to make early detection of risk. A successful application of genome wide association studies (GWAS) has been the identification of multiple common variants associated to complex traits such as T2D, renal and cardiovascular diseases. Taken individually, these genetic variants account for only a small effect size but the combination of hundreds or even thousands of them into polygenic risk scores (PRS) was recently introduced into models used to predict individual risk of diseases and their complications. What is a PRS? A PRS is a number that defines the level of risk a person has, to develop a disease or its complications over a defined period. The PRS considers the multiple genomic variants of a person and match them to “reference” individuals included in a database. The outcomes of the best matched individuals are then used to infer the outcomes of the new person before any clinical signs.
-
Research Area Keywords:Polygenic Risk Score; Diabetes complications; Diabetes Prevention; GWAS; single nucleotide polymorphisms
-
Research Type:Translational Research / Experimental Development
Research Area | Sub Research Area | Sub Speciality | Primary | Secondary | |
---|---|---|---|---|---|
3. Medical and Health Sciences
|
3.1 Basic Medicine
|
Human Genetics
|
Yes
|
No
|
|
3. Medical and Health Sciences
|
3.4 Medical Biotechnology
|
Gene-Based Diagnostics and Therapeutic Interventions
|
No
|
Yes
|
Institution
Institution | Country | Institution Role | |
---|---|---|---|
Weill Cornell Medical College in Qatar
|
Qatar
|
Collaborative Institution
|
|
McGill University
|
Canada
|
Collaborative Institution
|
|
Sidra Medicine
|
Qatar
|
Submitting Institution
|
Personnel
Role | Name | Affiliation | |
---|---|---|---|
Lead PI
|
Dr. Ammira Al-Shabeeb Akil
|
Sidra Medicine
|
|
PI
|
Dr. Ma'n Zawati
|
McGill University
|
|
PI
|
Prof. Shahrad Taheri
|
Weill Cornell Medical College in Qatar
|
|
PI
|
Prof. Pavel Hamet
|
Université de Montréal
|
|
PI
|
Prof. Pavel Hamet
|
Université de Montréal
|
|
PI
|
Dr. Younes Mokrab
|
Sidra Medicine
|
|
PI
|
Dr. Abeer Fadda
|
Sidra Medicine
|
|
PI
|
Prof. Johanne Tremblay
|
Université de Montréal
|
|
PI
|
Prof. Bartha Maria Knoppers
|
McGill University
|
|
PI
|
Dr. Patrick Bergeron
|
Bishop's University
|
|
PI
|
Dr. Jean Lachaine
|
Université de Montréal
|
|
Consultant
|
Dr. Monica Young
|
Hamad Medical Corporation
|
|
Consultant
|
Dr. Ma'n Zawati
|
McGill University
|
|
Consultant
|
Mr. Tariq Abu Saqri
|
Sidra Medicine
|
|
Consultant
|
Dr. Khalid Fakhro
|
Sidra Medicine
|